Using Lorlatinib for ALK Positive Lymphoma that has Relapsed

A Phase 2 Open Label Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma Previously Treated With ALK Inhibitors (CRU3)

This study is testing if Lorlatinib can help people with ALK-positive lymphoma who haven't had success with other treatments feel better and live longer.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 12 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: University of Milano Bicocca (Academic / other)
• Drugs / interventions: chemotherapy, Lorlatinib
• Locations: 2 sites (Monza, Italy/MB and 1 other locations)
• Trial ID: NCT03505554 on ClinicalTrials.gov

What this trial studies

This study evaluates the effectiveness of Lorlatinib, a targeted therapy, in patients with ALK-positive lymphoma who have not responded to previous treatments, including other ALK inhibitors. The trial aims to determine the objective response rates, progression-free survival, overall survival, and toxicity profile of Lorlatinib in this specific patient population. Additionally, it will assess the quality of life of participants and analyze the mutational status of ALK before and after treatment using advanced sequencing techniques. The study is designed for a small group of 12 patients who meet specific eligibility criteria.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with ALK-positive lymphoma that has relapsed or is refractory after at least one chemotherapy regimen and one ALK inhibitor.

Not a fit: Patients who have not been previously treated with ALK inhibitors or those with non-ALK-positive lymphomas may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new option for patients with ALK-positive lymphoma who have limited alternatives due to resistance to existing therapies.

How similar studies have performed: Other studies have shown promising results with Lorlatinib in similar patient populations, indicating potential for success in this approach.

Eligibility criteria

Inclusion Criteria:

1. Signed and dated Informed Consent approved by Local Ethical Committee before any protocol-specific screening procedures.
2. ALK+ Lymphoma diagnosed by IHC or FISH.
3. Refractory disease or relapse after at least one prior chemotherapy regimen (typically a minimum of 6 cycles of CHOP) and at least one ALK inhibitor; presence of measurable disease by physical examination, CT or CT-PET scan.
4. Any prior antitumor medical treatment or major surgeries must have been completed at least 14 days prior to initiation of study medication. This could not be respected if there is clear evidence of disease progression, manifested as growing pain attributable to the tumour, fever, growing tumour lesions, increasing LDH values. Systemic anti-cancer therapy completed within a minimum of 5 half-lives of study entry.
5. Able to take oral therapy.
6. Female or male, 18 years of age or older.
7. ECOG performance status 0-3.
8. Adequate organ function as defined by the following criteria:

   Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 2.5 x upper limit of normal (ULN) or AST and ALT ≤ 5 x ULN if liver function abnormalities are due to underlying malignancy Total serum bilirubin 1.5 x ULN (except patients with documented Gilbert's syndrome Creatinine ≤ 1.5 x ULN.
9. Adequate bone marrow function:

   Absolute neutrophil count (ANC) ≥ 1000/µL Platelets ≥ 50.000/µL Hemoglobin ≥ 9.0 g/dL The hematological values will not be considered in case of bone marrow involvement.
10. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
11. Female and male patients who are of childbearing potential must agree to use an effective form of contraception (2 forms of contraception) with their partners throughout participation in this study and for at least 90 days after the last dose of treatment.

Exclusion Criteria:

1. Current treatment on another therapeutic clinical trial.
2. Clinically significant cardiovascular disease (that is, active or \<3 months prior to enrollment): cerebral vascular accident/stroke, myocardial infarction, unstable angina, congestive heart failure (New York Heart Association Classification Class ≥ II)
3. Ongoing cardiac dysrhythmias of NCI CTCAE Grade ≥2: second-degree or third-degree AV block (unless paced) or any AV block with PR \>220 msec, uncontrolled atrial fibrillation of any grade, bradycardia defined as \<50 bpm (unless patient is otherwise healthy such as long-distance runners, etc.), machine-read ECG with QTc \>470 msec, or congenital long QT syndrome.
4. Pregnancy or breastfeeding.
5. Use of drugs or foods that are known strong or moderate CYP3A4 inhibitors, inducers and substrates; drugs that are CYP2C9 substrates; drugs that are strong CYP2C19 inhibitors; drugs that are strong CYP2C8 inhibitors; and drugs that are P-gp substrates.
6. Prior malignancy other than basal cell carcinoma , if original diagnosis happened in the last 5 years.
7. Patients with predisposing characteristics for acute pancreatitis according to investigator judgment (e.g. uncontrolled hyperglycemia, current gallstone disease, alcoholism).
8. Hypertriglyceridemia ≥ grade 1.
9. Active and clinically significant bacterial, fungal, or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS) related illness.
10. Other severe acute or chronic medical or psychiatric conditions, or laboratory abnormalities that would impart, in the judgment of the investigator and/or sponsor, excess risk associated with study participation or study drug administration.

Where this trial is running

Monza, Italy/MB and 1 other locations

• Asst-Monza — Monza, Italy/MB, Italy (Recruiting)
• UOC Ematologia, Ospedale S. Eugenio — Roma, Italy (Recruiting)

Study contacts

• Principal investigator: Carlo Gambacorti-Passerini, Md — University of Milano Bicocca
• Study coordinator: Silvia Mori, PhD

Conditions Anaplastic Large Cell Lymphoma, ALK-Positive; ALK; relapsed; lorlatinib